AGP Picks
View all

Buminate market outlook points to growth in critical care demand

Oct. 30, 2026
Buminate market outlook points to growth in critical care demand
By AI, Created 16:30 UTC, Oct 30, 2026, AGP -

The Business Research Company says the global Buminate market is set for growth through 2035, driven by rising liver disease, higher healthcare spending and more clinical trials. North America holds the largest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Buminate is a human albumin therapy used in shock, burns, trauma and surgery, so demand tracks critical care needs. - Rising use could matter for hospitals managing blood volume replacement, hypoalbuminemia and complications tied to liver disease. - The market outlook also signals where plasma-derived therapies may see the strongest commercial growth through 2035.

What happened: - The Business Research Company released its Buminate Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report covers global market size, growth drivers, trends and regional prospects for Buminate. - The report says North America held the largest Buminate market share in 2025. - The report expects Asia-Pacific to be the fastest-growing region in the coming years. - The report includes expanded strategic intelligence features such as market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, and key technology and future trend analysis.

The details: - Buminate is a branded human albumin solution sourced from human plasma. - The product is designed to restore or maintain circulating blood volume. - Buminate works by increasing blood osmotic pressure, which helps draw fluid into the bloodstream and support circulation and tissue perfusion. - The report identifies rising liver disease cases as a major growth driver. - Liver diseases cited in the report include cirrhosis, hepatitis, fatty liver disease and liver cancer. - The report links liver disease growth to infections, toxins, genetic factors and chronic alcohol use. - The report also cites excessive drinking, poor diet and obesity as contributors to liver damage and fat buildup. - The report says Buminate can help manage edema and ascites by restoring blood volume and osmotic pressure. - The report points to rising global healthcare spending as another support for market growth. - The report says healthcare spending is rising because of aging populations, chronic illness, medical inflation, technology advances and the aftereffects of COVID-19. - The report says investment in healthcare infrastructure increases demand for therapies such as Buminate in conditions including hypoalbuminemia and trauma. - The report cites UK healthcare spending growth of 5.6% from 2022 to 2023, reaching about $317.63 billion, according to the Office for National Statistics. - The report says more clinical trials are supporting market expansion by generating safety and efficacy data. - ClinicalTrials.gov reported that clinical trial results publications rose from 4,024 in 2022 to 5,063 in 2023. - The report says historical market growth has been supported by established clinical uses, more surgical procedures, expansion of intensive care units, a documented safety profile and reliance on plasma-derived therapies. - The report forecasts continued growth from more trauma cases, more surgeries, ICU expansion, demand for rapid volume replacement and better plasma fractionation capabilities. - The report says key trends include sustained albumin use in critical care, stronger demand in trauma and burn care, wider use for surgical volume support, preference for plasma-derived proteins and more intensive care admissions. - The report says the Buminate market is tied to the broader global demand for therapeutic plasma-derived products.

Between the lines: - The report frames Buminate as a mature therapy with demand that expands when hospitals face more severe disease burdens and higher acuity care. - The strongest growth drivers are not new drug launches but broader system pressures, including liver disease, trauma, surgery and ICU utilization. - The regional split suggests established demand in North America and faster expansion potential where healthcare investment and disease burden are rising.

What's next: - The report expects market growth to continue through 2035 as critical care demand rises. - Hospitals and providers are likely to keep using albumin therapies for volume support in surgery, trauma and liver-related complications. - The company is also promoting report access through a free sample and the full market report, along with direct contact options for its sales team.

The bottom line: - Buminate’s market story is being driven by critical care demand, liver disease and broader healthcare spending, with North America leading today and Asia-Pacific set to outpace other regions.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

New Products Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

New Products Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.